NRM 2021
supported by:

To search for a specific ID please enter the hash sign followed by the ID number (e.g. #123).
Keyword Contributions
5-ht2a receptor P-WE-6-01
5ht2c S-02-05
5xfad P-WE-6-05
[³h]abp688 P-TH-8-23
[³h]ucb-j P-WE-6-17
[¹²⁴i]ibeta P-TU-1-09
[¹²⁵i]-ippi P-TU-3-10
[¹²⁵i]iaza P-TU-1-18
[¹¹c]-(r)-pk11195 P-TU-4-03
[¹¹c]-ucb-j P-TU-3-15S-02-04
[¹¹c]carfentanil P-WE-7-09
[¹¹c]carfentanil positron emission tomography P-TH-9-09
[¹¹c]cimbi-36 P-WE-6-01S-02-05
[¹¹c]colchicine P-WE-6-06
[¹¹c]cppc P-TU-1-17
[¹¹c]dtbz P-TH-8-18
[¹¹c]hd-800 P-WE-6-06
[¹¹c]martinostat P-TH-8-01
[¹¹c]mk-6884 P-WE-6-11
[¹¹c]nop-1a S-03-10
[¹¹c]pbr2 P-TU-4-05
[¹¹c]pbr28 P-TU-4-01
[¹¹c]raclopride S-02-06
[¹¹c]ro15-4513 P-TU-4-06
[¹¹c]ucm1014 P-TU-1-02
[¹¹c]ucm765 P-TU-1-02
[¹¹c]verubulin P-WE-6-06
[¹⁵o] P-WE-5-10
[¹⁵o]-oxygen P-WE-5-11
[¹⁵o]-water P-WE-5-06
[¹⁵o]water P-WE-5-05
[¹⁸f]-bccp-ef S-02-04
[¹⁸f]-fdg pet P-WE-5-08
[¹⁸f]bavarostat P-WE-6-19
[¹⁸f]ekz-001 P-WE-6-19
[¹⁸f]fdg brain pet P-TU-3-17
[¹⁸f]fdg pet P-TU-2-03
[¹⁸f]fdg suvr P-WE-5-03
[¹⁸f]fds pet imaging P-TU-1-12
[¹⁸f]feppa P-TU-4-08
[¹⁸f]flortaucipir P-TH-8-14
[¹⁸f]flotaza P-TU-1-09
[¹⁸f]fluoroagomelatine P-TU-1-02
[¹⁸f]fpeb P-TU-3-18
[¹⁸f]nos S-02-10
[¹⁸f]synvest-1 P-WE-6-09
a2a receptor P-TU-1-13
acetylcholine receptors P-WE-6-08
addiction P-TH-9-05
adenosine a1 receptor P-WE-7-05
adenosine receptor P-TU-1-13P-WE-7-04
adrenergic receptor P-WE-7-11
aging P-TU-1-15P-WE-7-10
alcohol-use disorder S-03-10
alpha-synuclein P-WE-6-02P-WE-6-10S-01-02
alpha7 P-WE-6-08
alzheimer's disease P-TH-10-02P-TH-10-05P-TH-10-07P-TH-8-04P-TH-8-05P-TH-8-14P-TH-8-16P-TH-8-17P-TH-8-19P-TH-8-20P-TH-8-21P-TH-8-22P-TH-8-24P-TH-8-25P-TU-1-03P-TU-1-04P-TU-1-05P-TU-1-09P-TU-1-10P-TU-1-11P-TU-1-18P-TU-1-22P-TU-3-02P-TU-3-05P-TU-3-09P-TU-3-10P-TU-3-14P-TU-3-16P-WE-6-05P-WE-7-08S-01-03S-01-07S-03-01S-03-02S-03-03S-03-04S-03-05
amnestic mci P-TU-3-05
amphetamine S-02-06
amplitude of low frequency fluctutations S-02-04
amyloid P-TH-10-07P-TH-8-03P-TH-8-05P-TH-8-20P-TH-8-21P-TH-8-25P-TH-8-26P-TU-1-05P-TU-1-09P-TU-1-18P-TU-4-09P-WE-6-04P-WE-6-05S-01-03S-01-05S-03-01S-03-02
amyotrophic lateral sclerosis P-TH-8-02
animal model S-02-01
anosmia P-TH-8-19
antidepressant treatment response prediction P-TH-9-13
apoe S-03-03
arterial spin labeling P-WE-5-09P-WE-5-10
astrocytes P-TU-1-05
asymmetry P-TU-4-03
atlas P-WE-7-01P-WE-7-07
atp-binding cassette P-TU-1-06
autism P-TH-9-11
autism spectrum disorder P-TH-9-12S-03-08
autism spectrum disorder (asd) P-TH-8-08
autoradiography P-TH-8-23P-TU-3-06P-TU-3-18P-TU-4-04P-WE-6-17P-WE-7-01P-WE-7-08S-01-02
basal ganglia encephalitis P-WE-6-07
bayes factor P-TU-3-21
bayesian P-TU-2-02P-TU-2-05
bayesian modeling P-TU-3-04
behavioral challenge P-TU-2-04
behavioral psychology P-TH-8-08
between-subject variance P-TU-4-07
binding P-TU-4-03
binding potential P-TU-3-08P-TU-3-12
binding potential (bpnd) P-TU-4-08
biodistribution P-TU-1-16
biomarker P-TH-10-05S-02-01
biomarkers P-TH-8-20S-03-01
blood biomarker P-TH-10-02
blood brain barrier P-TU-1-12S-03-09
blood-free pet quantification P-TU-2-01
bmi P-WE-7-10
bolus-infusion P-WE-6-01
braak stages P-TU-3-16
brain P-WE-7-05
brain development P-WE-6-18
brain mapping P-TU-3-13
brain pet P-TU-3-08S-01-08
caffeine P-WE-7-04
camp P-TU-1-08
carbon-11 P-TU-1-07
carfentanil P-WE-7-07
cbd P-TU-1-11
centiloids P-TH-8-26
cerebral amyloid angiopathy S-01-05
cerebral blood flow P-TH-8-03P-TH-8-14P-WE-5-01P-WE-5-06S-01-03S-03-02
cerebral cortex P-TU-3-16
cerebral metabolism P-WE-5-11
cerebrovascular disease S-01-10
cerebrovascular reactivity S-01-10
chemogenetics S-01-04
childhood trauma P-TH-9-10
choroid plexus P-TH-8-09S-03-09
chronic pain P-TH-10-06
chronic traumatic encephalopathy P-TH-8-11
clearing agent P-WE-6-04
click-reaction P-WE-6-04
clinical assessment P-TH-8-13
clinical trials P-TH-8-08
cmrglu P-TU-2-03
cmro2 P-WE-5-11
cocaine P-WE-6-17
cognition P-TH-8-14P-TU-3-07
cognitive decline P-TH-10-05P-TU-4-09
cognitive reserve P-TH-10-08
compartmental modeling P-TU-2-05
compartmental modelling P-WE-7-11
connectivity P-TH-8-05P-TH-8-16
cortical thickness P-TH-8-25
covid P-TH-10-07
covid-19 P-TH-10-03
cox-2 P-TU-1-23
crispr/cas9 S-02-03
csf P-TH-10-04P-TH-8-22
csf1r P-TU-1-04
cyclooxygenase 1 P-TU-1-20
cyclooxygenase 2 P-TU-1-20
cyclooxygenase-1 and -2 P-TU-1-01
cyclooxygenase-2 P-TU-1-14
d3 receptors P-TU-1-21
data harmonization P-TU-3-08
data-driven methods S-02-08
datscans P-TU-3-04
dementia P-TH-8-17P-WE-5-10
demyelination P-WE-6-14
denoising S-02-08
depression P-TH-9-02P-WE-5-02S-03-09
deschloroclozapine (dcz) S-01-11
designer receptor exclusively activated by designer drugs (dreadd) S-01-11
diprenorphine P-WE-7-07
direct-4d reconstruction P-TU-4-07
disease progression S-03-04
disease progression models P-TU-3-04
displacement P-WE-6-01
docosahexaenoic acid P-TU-4-01
dopamine P-TH-9-05P-TH-9-07P-TU-1-21P-TU-2-04P-TU-3-19P-WE-7-03S-02-06
dopamine d2-receptor P-TH-9-15
dopamine release P-TH-9-06S-02-08
dopamine synthesis P-TH-9-06S-02-07
dopamine transporter P-TH-8-15
dopaminergic degeneration P-WE-6-02
dopaminergic system P-TU-3-01P-WE-7-02
dorsal attention network P-WE-6-16
dosimetry P-TU-1-16
down syndrome P-TH-8-26
dreadds S-01-04
drug-drug interaction P-TU-1-06
dtbz P-TH-8-06
dti P-TH-8-02P-TH-9-15
dynamic (dvr/bpnd) P-TU-3-14
dynamic functional connectivity P-WE-5-08
dynamic pet P-TU-4-06
dynamics P-TU-3-07
early detection P-TU-3-09
early life stress P-TH-9-07
early stopping P-TU-3-21
ec50 S-01-08
endocannabinoid system S-02-09
enzyme P-TU-1-19
epigenetics S-03-08
epilepsy P-TH-8-07
er176 P-WE-6-07
executive function P-WE-6-16
externalizing traits P-TH-9-07
extracerebral signal S-01-07
f18-cpfpx P-WE-7-05
fatty acid hydrolase S-02-09
fazin3 P-TU-1-22
fdg P-TH-9-13P-WE-5-01P-WE-5-02
fdg-pet P-TU-3-05
fdopa pet S-03-06
fear P-WE-7-03
first-in-human P-TU-1-17
fluorine-18 P-TU-1-13P-TU-3-02
fmri S-02-04
focused ultrasound P-TU-1-12
fpeb P-TH-9-02
free water P-TH-8-24
frontal cortex P-TU-3-12
frontotemporal dementia P-TU-1-15
ftc146 S-01-01
fully quantitative P-TH-9-13
function P-TU-3-07
functional connectivity P-WE-5-04S-02-03
functional mri P-TH-8-03P-WE-5-09
functional pet P-WE-5-07P-WE-5-09S-02-07
gaba P-WE-7-01
gender P-WE-7-05
gene editing S-02-03
gene expression P-TU-3-06
genes S-02-03
genetics S-03-05
geometric transfer matrix P-TU-2-05
glial activation P-TH-10-04
glial cells P-TH-10-06
glioma P-WE-5-05
glucose metabolism P-WE-5-01P-WE-5-04
glun2b subunit P-TU-1-16
glutamate P-TH-9-06P-TH-9-16
glycogen synthase kinase-3 P-TU-1-01
graph theory P-WE-5-08
gray matter volume P-TU-3-12
grey matter volume P-TH-9-06
hdac S-03-08
hdac6 P-WE-6-19
healthy P-TH-10-03
healthy ageing P-WE-6-09
heterogeneity P-WE-5-05
hippocampus P-TH-8-23
histone deacetylases P-TH-8-01
ht1a receptors P-TU-1-21
human P-TH-9-04
human embryonic stem cells P-WE-6-12
human hippocampus P-WE-7-08
huntington's disease S-02-01
i-124 P-WE-6-05
idif P-TU-2-03P-TU-4-05
image analysis P-TU-3-10P-TU-4-02
image derived input function P-TU-2-05
image quality P-TU-3-17
image-derived input function P-WE-5-06
image-derived input function (idif) P-TU-4-08
imaging biomarker P-TH-10-02
immune activation P-TH-9-14
immune system P-TH-8-20
independent component analysis P-TU-3-05
inflammation P-TH-10-06P-TU-1-20
injected radioactivity P-TU-3-21
inter-scanner P-TU-3-08
internalization S-02-06
ippi tau P-WE-7-08
irreversible kinetics P-TU-2-01
keynote KN-02-01KN-03-01
kinetic modeling P-TU-2-01P-TU-2-04P-TU-3-03P-TU-3-18P-TU-3-19
kinetic modelling P-WE-6-09
kinetic models S-01-11
lassen plot S-01-08
lateral ventricles P-TH-8-09
lateralization P-TH-8-10
lesions P-TH-8-01
lewy bodies P-TU-4-02
limbic system P-TH-9-12
lipopolysaccharide P-WE-6-03
longitudinal P-TU-3-15
longitudinal [¹⁸f]flortaucipir pet P-TU-3-14
m4 machr P-WE-6-11
macrophage colony stimulating factor 1 receptor P-TU-1-17
magl P-TU-1-19
major depressive disorder P-TH-9-10P-TH-9-13
mao-a S-03-01
mapping P-WE-6-16
mdd P-TU-1-08
medial temporal lobe P-TH-8-10
melatonin receptors P-TU-1-02
membrane transporter P-TU-1-06
mental health P-TH-9-07
mesial temporal lobe epilepsy P-TH-8-23
metabolic connectivity mapping P-WE-5-04
metabolism P-TH-9-10P-WE-5-07
metabotropic glutamate receptor 5 (mglur5) P-WE-6-15
mglur5 P-TH-8-23P-TH-9-02P-TU-3-02
mgur5 P-TH-9-04
mhtt S-02-01
mice P-WE-6-09
microdialysis P-TH-9-16
microglia P-TH-8-19P-TU-1-03P-TU-1-04P-TU-1-17P-TU-1-23P-WE-6-07
microparameters P-TU-2-03
microstructure P-TH-8-24
microtubules P-WE-6-06
mild cognitive impairment P-TU-1-05
mild traumatic brain injury P-TH-8-11S-02-09
minipigs P-WE-6-12P-WE-6-13
mk-6240 S-01-07
mk2640 P-TH-8-22
modeling P-TU-1-19
modelling P-WE-7-06
molecular connectivity P-TU-4-06
molecular imaging S-02-02
money P-TU-3-21
monkey S-01-04
monoamine oxidase P-TU-4-02
monoamine oxidase a P-TU-1-22
monoamine oxidase b P-WE-6-03
morphine S-03-07
mouse imaging P-TU-1-01
mri P-TH-9-10P-WE-5-10
mrna P-TH-10-01P-WE-7-01
mrs P-TH-10-03
mu opioid receptor P-TH-9-09
mu-opioid receptor P-WE-7-09
multi-modal S-03-04
multi-site pet P-TU-3-03
multi-tracer pet P-TH-8-12
multicenter collaboration P-TH-9-14
multimodal analysis P-TH-8-03
multimodal imaging P-TH-10-01
multimodal neuroimaging P-TH-9-08S-02-04
multiple regression modelling P-WE-5-03
multiple sclerosis P-TH-8-01
multiple system atrophy S-01-02
myelin P-TU-3-13
n-methyl-d-aspartate P-TH-9-16
net influx rate P-TU-2-01
network P-TH-8-05
neurobiology P-TU-3-13
neurodegeneration P-TH-10-05P-TH-8-09P-TU-1-13S-03-04
neurodevelopmental disabilities P-TH-8-08
neuroepigenetics P-TH-8-01
neuroimaging P-TH-9-16P-TU-3-09P-WE-6-11S-02-02
neuroimmune system S-03-07
neuroinflamation P-TH-8-02
neuroinflammation P-TH-10-03P-TH-10-07P-TH-8-16P-TH-8-25P-TU-1-10P-TU-1-14P-TU-1-23P-WE-6-03S-02-10S-03-03S-03-09
neuronal plasticity-related proteins P-TH-9-01
neuropathic P-TH-10-06
neuropharmacology P-TU-1-06
neuroplasticity P-WE-5-04
neuropsychiatric disorders P-TU-1-16
neuropsychologytau P-TH-8-13
neuroreceptor template P-WE-7-06
neurotransmitter release P-WE-7-03
neurotransmitters P-TU-4-04
neutrophils P-TH-8-20
nhp P-WE-6-11
nifene P-WE-7-08
nmda receptor P-TU-1-16
nondisplaceable binding potential P-TH-9-12
nonverbal memory P-TH-8-10
norepinephrine P-WE-7-10
norepinephrine transporter P-TH-9-01
novel pattern analysis P-TU-3-01P-WE-7-02
nr2b-sme S-01-01
nr2b/nmda receptor S-01-01
nucleus accumbens P-TH-9-09
obesity P-WE-5-01
occupancy S-01-08
olfaction P-TH-8-19
oncology P-TU-1-01
opioid P-TH-9-05
opioid receptor P-WE-7-07
opioid use disorder S-03-07
optimization P-TU-3-17
optogenetics S-01-09
oxidative stress P-WE-6-10
oxygenation S-01-10
p-tau P-TH-8-22
p-tau biomarkers P-TH-10-02
pam P-WE-6-11
pandas P-WE-6-07
parametric-molar P-TU-4-07
parkinson's disease P-TH-8-15P-TU-3-01P-WE-6-10P-WE-6-12
parkinson’s disease P-TH-8-06P-TH-8-12P-TH-8-18P-TU-1-22P-TU-3-04P-TU-4-02P-TU-4-09P-WE-7-02S-01-02S-02-10
partial volume correction P-TU-2-05P-TU-3-03
pbif P-TU-4-05
pd rodent model P-WE-6-02
pde4b P-TU-1-08
perfusion P-WE-5-05S-01-10
pet P-TH-9-01P-WE-7-11
pet [¹⁸f]flortaucipir P-TH-8-11
pet imaging P-TU-1-01P-TU-3-02P-WE-6-02P-WE-6-12P-WE-7-10S-01-05S-02-01
pet reporter systems S-02-02
pet tracer evaluation S-01-02
pet-bids P-TU-3-11
pet-imaging P-TH-8-21
pet-mr P-TH-8-02
pet-mri P-WE-5-07S-03-08
pet/ct P-WE-6-05S-02-10
pet/ct studies P-TU-1-09
pet/fmri S-02-03
pet/mr P-WE-5-01P-WE-5-09
pet/mri P-TH-8-03P-TU-2-04P-TU-3-19P-WE-5-06P-WE-5-11S-01-10S-02-06
pf-06445974 P-TU-1-08
pharmacokinetic P-TU-1-06P-TU-1-12P-TU-2-02P-TU-3-13
photoacoustic P-TH-9-16
pick's disease P-TU-1-11
piglets P-WE-6-08
polygenic score P-TU-3-12
population variability P-WE-7-06
positron emission tomography (pet) P-TH-8-08
positron-emission tomography P-TU-1-14
post-traumatic stress disorder P-TH-9-03
posttraumatic stress disorder P-WE-6-15S-02-09
pre-clinical imaging P-TU-1-23P-WE-6-18
pre-targeting P-WE-6-04
precision medicine S-03-06
preclinical P-WE-6-13
preclinical alzheimer's P-WE-6-16
principal component analysis S-02-08
propagation P-TU-3-16
proteome P-TH-10-01
proteomics P-WE-6-15
psams S-01-04
psychiatry P-TH-9-07
psychosis P-TH-9-14S-03-06
quantification P-TU-3-14P-TU-3-17S-01-03
qupath P-TU-3-10P-TU-4-02
r1 S-03-02
raclopride P-WE-7-03
radiochemistry P-TU-1-07
reactive oxygen species P-WE-6-10
receptor desensitization P-WE-7-09
receptor trafficking P-WE-7-09
receptors P-TU-4-04
reconstruction P-TU-3-17P-TU-4-04
reference region P-TU-3-18
refractory P-TH-8-07
rejection sensitivity P-TH-9-09
reliability P-WE-7-11
rem sleep behaviour disorder P-TH-8-18
resting state P-WE-5-03
resting state brain networks P-WE-5-08
reward circuitry S-03-07
reward processing S-02-07
rheumatoid arthritis P-TU-1-20
ripk1 P-TU-1-03P-TU-1-10
rodent models P-WE-6-15
rostrace P-WE-6-10
scanning window P-TH-8-06
schizophrenia P-TH-9-08P-TH-9-14P-TH-9-15
sequential testning P-TU-3-21
serotonin S-02-05
serotonin receptor P-TU-3-12
sigma receptor S-01-01
signal standardization P-TU-4-06
simulations S-01-08
simultaneous estimation (sime) P-TU-4-08
simultaneous estimation (sime) of the arterial input function P-TH-9-13
simultaneous fpet/fmri S-01-09
simultaneous pet/fmri P-WE-5-03P-WE-5-08
sleep P-WE-5-07
small vessel disease P-TH-8-24
social isolation P-TH-9-01
source-to-target modeling P-TU-2-01
spatial patterns P-TH-8-12
spatio-temporal patterns P-TU-3-01P-WE-7-02
spectral analysis S-01-07
static (suvr) P-TU-3-14
statistics P-TU-2-02
stress-enhanced fear learning (sefl) P-WE-6-15
structure P-TU-3-07
subjective cognitive decline S-03-02
sucrose P-TH-9-05
sucrose-consumption P-WE-6-13
suicide P-TH-9-04
sulfonylurea receptor 1 P-TU-1-07
support vector machine P-TH-8-22
suvr bias S-01-03
sv2a P-TH-9-02P-TU-3-15P-TU-3-20P-TU-4-07P-WE-6-13P-WE-6-17
synapses P-TU-3-20
synaptic activity P-TH-8-04
synaptic density P-TH-8-04P-TH-8-15P-TH-9-11P-TU-1-15P-TU-3-15P-WE-6-17P-WE-6-18
synaptic dysfunction P-TH-10-04
target engagement P-TH-9-12
target occupancy P-WE-6-19
tau P-TH-10-04P-TH-10-07P-TH-8-04P-TH-8-05P-TH-8-11P-TH-8-13P-TH-8-14P-TH-8-16P-TH-8-17P-TH-8-21P-TH-8-25P-TH-8-27P-TU-1-18P-TU-3-10P-TU-3-16P-WE-6-16S-03-01S-03-03S-03-05
tau pet P-TH-8-10S-01-07
tau proteins P-TH-8-19
tauopathies P-TU-1-11
tauopathy P-TU-3-09
test-retest P-TU-3-08P-TU-3-15
test-retest reliability P-WE-5-09
thalamus P-TH-9-15
tms P-WE-5-02
tracer development S-01-05
transcriptome P-TH-10-01
trauma P-TH-9-04
traumatic brain injury P-TH-8-09P-WE-6-14
treatment response S-03-06
tspo P-TH-9-03P-TH-9-14P-TU-4-01P-TU-4-03P-WE-6-03S-03-07
twins S-03-05
two-tissue compartment modelling P-TU-4-08
ucb-j P-TH-9-02P-TH-9-11P-TU-3-20P-WE-6-13
upper motor neuron P-TH-8-02
vagus nerve stimulation P-WE-6-08
variational bayesian P-TU-2-03
vascular risk factor P-TH-10-05
vasculature P-TU-3-13
vbm P-TH-9-06
verbal fluency P-TH-8-21
verbal memory P-TH-8-13
visual memory P-TH-8-13
vmat2 P-TH-8-18
voxel-based analysis P-TU-3-05
voxelwise analysis S-02-08
white matter P-TH-8-24
within-scan challenges P-WE-6-01
within-subject variance P-TU-4-07
yohimbine P-WE-7-11